CytomX Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	76.2	138.1	101.21	53.16	37.31
Revenue Growth (YoY)	-44.82%	36.45%	90.38%	42.48%	-45.47%
Gross Profit	76.2	138.1	101.21	53.16	37.31
Selling, General & Admin	29.84	29.73	30.02	42.85	39.16
Research & Development	68.73	83.38	77.68	111.65	114.19
Total Operating Expenses	98.57	113.11	107.7	154.5	153.35
Operating Income	-22.36	25	-6.48	-101.34	-116.04
Interest Income	5.21	7.14	9.84	1.68	0.26
Other Non-Operating Income (Expense)	0.03	-0.04	-0.03	0.34	-0.08
Total Non-Operating Income (Expense)	5.23	7.1	9.81	2.02	0.17
Pretax Income	-17.13	32.09	3.32	-99.32	-115.87
Provision for Income Taxes	0.24	0.22	3.89	-	-
Net Income	-20.37	31.87	-0.57	-99.32	-115.87
Net Income Attributable to Preferred Dividends	3	-	-	-	-
Net Income to Common	-20.37	31.87	-0.57	-99.32	-115.87
Shares Outstanding (Basic)	138	84	74	66	64
Shares Outstanding (Diluted)	138	85	74	66	64
Shares Change (YoY)	62.77%	14.82%	12.27%	2.48%	39.01%
EPS (Basic)	-0.15	0.38	-0.01	-1.51	-1.81
EPS (Diluted)	-0.15	0.38	-0.01	-1.51	-1.81
Shares Outstanding	170.19	80.1	73.81	66.23	65.39
Free Cash Flow	-75.81	-86.54	-56.88	-112.53	-120.64
Free Cash Flow Per Share	-0.55	-1.02	-0.77	-1.71	-1.88
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%
Operating Margin	-29.35%	18.10%	-6.41%	-190.61%	-311.00%
Profit Margin	-22.79%	23.08%	-0.56%	-186.82%	-310.54%
FCF Margin	-99.48%	-62.66%	-56.19%	-211.67%	-323.33%
EBITDA	-20.99	26.76	-4.31	-98.89	-113.34
EBITDA Margin	-27.54%	19.38%	-4.26%	-186.02%	-303.75%
EBIT	-22.36	25	-6.48	-101.34	-116.04
EBIT Margin	-29.35%	18.10%	-6.41%	-190.61%	-311.00%
Effective Tax Rate	-1.39%	0.70%	117.12%	0.00%	0.00%

Updated Mar 16, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q